ArticleFrontiers in neurology2021
Multiparametric Microstructural MRI and Machine Learning Classification Yields High Diagnostic Accuracy in Amyotrophic Lateral Sclerosis: Proof of Concept.
Article in Frontiers in neurology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 20 citations in OpenAlex.
- Machine learning diagnostic model for amyotrophic lateral sclerosis analysis using MRI-derived features.Neuroradiology · 2025Article
- Magnetic Resonance Neuroimaging in Amyotrophic Lateral Sclerosis: A Comprehensive Umbrella Review of 18 Studies.Brain sciences · 2025Review
- Review
- Potential of neuroimaging as a biomarker in amyotrophic lateral sclerosis: from structure to metabolism.Journal of neurology · 2024Review
- Toward diffusion tensor imaging as a biomarker in neurodegenerative diseases: technical considerations to optimize recordings and data processing.Frontiers in human neuroscience · 2024Review
- Digital Alternative Communication for Individuals with Amyotrophic Lateral Sclerosis: What We Have.Journal of clinical medicine · 2023Review
- Review
- Diffusion Tensor Imaging in Amyotrophic Lateral Sclerosis: Machine Learning for Biomarker Development.International journal of molecular sciences · 2023Review
- Artificial neural networks for non-linear age correction of diffusion metrics in the brain.Frontiers in aging neuroscience · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The potential of multiparametric quantitative neuroimaging has been extensively discussed as a diagnostic tool in amyotrophic lateral sclerosis (ALS). In the past, the integration of multimodal, quantitative data into a useful diagnostic classifier was a major challenge. With recent advances in the field, machine learning in a data driven approach is a potential solution: neuroimaging biomarkers in ALS are mainly observed in the cerebral microstructure, with diffusion tensor imaging (DTI) and texture analysis as promising approaches. We set out to combine these neuroimaging markers as age-corrected features in a machine learning model with a cohort of 502 subjects, divided into 404 patients with ALS and 98 healthy controls. We calculated a linear support vector classifier (SVC) which is a very robust model and then verified the results with a multilayer perceptron (MLP)/neural network. Both classifiers were able to separate ALS patients from controls with receiver operating characteristic (ROC) curves showing an area under the curve (AUC) of 0.87-0.88 ("good") for the SVC and 0.88-0.91 ("good" to "excellent") for the MLP. Among the coefficients of the SVC, texture data contributed the most to a correct classification. We consider these results as a proof of concept that demonstrated the power of machine learning in the application of multiparametric quantitative neuroimaging data to ALS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.